

Docket No.: 129285-00012

UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT: 9,463,114
INVENTORS: STEVEN A. ODRICH; LIANE C. GLAZER
FILED: AUGUST 29, 2014
ISSUED: OCTOBER 11, 2016
TITLE: PUNCTAL PLUG WITH ACTIVE AGENT

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Ocular Therapeutix
Petitioner

v.

Mati Therapeutics, Inc.
Patent Owner

Case IPR2019-00442

**PETITION FOR *INTER PARTES* REVIEW OF U.S. PATENT NO. 9,463,114
UNDER 35 U.S.C. § 312 AND 37 C.F.R. § 42.104**

TABLE OF CONTENTS

I. INTRODUCTION.....	1
A. The Parties	1
B. The ‘114 Patent Is Invalid	2
II. MANDATORY NOTICES	3
A. Real Party-in-Interest	3
B. Related Matters	3
C. Counsel	3
D. Service Information.....	4
III. CERTIFICATION OF GROUNDS FOR STANDING	4
IV. OVERVIEW OF CHALLENGE AND RELIEF REQUESTED.....	4
A. Prior Art Patents and Printed Publications	4
B. Relief Requested	5
V. BACKGROUND OF THE TECHNOLOGY	5
A. Lacrimal Punctum and Canaliculus	5
B. Punctal Plugs.....	6
C. Ophthalmic Drug Delivery	8
VI. THE ‘114 PATENT	9
A. Claims	9
B. Challenged Claims	9
C. Summary of the Specification	12
D. Summary of the Prosecution History	13
E. Level of Ordinary Skill in the Art.....	18
VII. CLAIM CONSTRUCTION	19
VIII. THE PRIOR ART	22
A. Schmitt.....	22
B. Higuchi	24
C. Cagle.....	26
D. Physician’s Desk Reference for Ophthalmic Medicines (2003).....	26

IX. GROUNDS FOR CHALLENGE27

 A. Ground 1: Claims 1, 3, 6-8, 10 and 13 Are Anticipated by Schmitt29

 B. Ground 2: Claims 1, 3, 6-8, 10, 13, and 14 Are Obvious Over Schmitt in
 View of Higuchi.....42

 C. Ground 3: Claims 1, 3, 6-8, 10, 13, and 14 Are Obvious Over Schmitt in
 View of PDR (2003)53

 D. Ground 4: Claims 1, 3, 5-8, 10, and 12-14 Are Obvious Over Schmitt in
 View of Cagle61

X. Conclusion70

TABLE OF EXHIBITS

Exhibit	Description
Ex. 1001	US Patent No. 9,463,114 to Odrich <i>et al.</i> (“114 Patent”)
Ex. 1002	Declaration of Reza Dana, M.D., executed December 14, 2018 (“Dana Decl.”)
Ex. 1003	Curriculum Vitae of Reza Dana, M.D. (“Dana CV”)
Ex. 1004	US Patent No. 5,469,867 to Schmitt (filed September 2, 1992) (“Schmitt”)
Ex. 1005	US Patent No. 3,993,071 to Higuchi <i>et al.</i> (filed July 24, 1975) (“Higuchi”)
Ex. 1006	Physician’s Desk Reference for Ophthalmic Medicines (2003) (published 2002) (“PDR2003”)
Ex. 1007	US Patent No. 6,509,327 to Cagle <i>et al.</i> (filed May 19, 2000) (“Cagle”)
Ex. 1008	File History of US Application 14/472,844 (“844 FH”)
Ex. 1009	W. Foulds “Intra-Canalicular Gelatin Implants In the Treatment of Kerato-Conjunctivitic Sicca,” BRIT. J. OPHTHAL. 45:625 (1961) (“Foulds”)
Ex. 1010	STEDMAN’S CONCISE MEDICAL DICTIONARY FOR THE HEALTH PROFESSIONS, 3rd Ed., Dirckx, J. (ed.) (“Stedman”)
Ex. 1011	Snell, R., CLINICAL ANATOMY FOR MEDICAL STUDENTS, 5th Ed. (1995) (“Snell”)
Ex. 1012	US Patent No. 3,949,750 to Freeman (filed October 7, 1974) (“Freeman”)
Ex. 1013	US Patent No. 6,196,993 to Cohan <i>et al.</i> (filed April 19, 1999) (“Cohan”)
Ex. 1014	Miller, J. and Wolf, E.H., “Antazoline phosphate and naphazoline hydrochloride, singly and in combination for the treatment of allergic conjunctivitis,” ANN. ALLERGY, 35:81-86 (1975) (“Miller”)
Ex. 1015	US Patent No 5,283,063 to Freeman (filed Jan. 31, 1992) (“Freeman 94”)
Ex. 1016	US Patent No. 5,322,691 to Darougar <i>et al.</i> (filed June 29, 1993) (“Darougar”)
Ex. 1017	File History of the ’202 Patent (“’202 FH”)
Ex. 1018	US Patent No. 3,828,777 to Ness (filed November 8, 1971) (“Ness”)

U.S. Patent 9,463,114
Petition for *Inter Partes* Review

Ex. 1019	Berkow, R. ed., THE MERCK MANUAL, 13TH ED. (1977) (“Merck”)
Ex. 1020	“CMC Chemical Profile,” icis.com (“CMC”)
Ex. 1021	Kibbe, A., ed., Handbook of Pharmaceutical Excipients 3rd Ed. (2000) (“Handbook”)
Ex. 1022	U.S. Patent No. 9,309,313, entitled “Therapeutic Compositions for Treatment of Ocular Inflammatory Disorders” (“Dana313”)
Ex. 1023	US Application Publication No. 2007/0265341, entitled “Compositions and Methods for Treating Eye Disorders and Conditions” (“Dana341”)
Ex. 1024	Netter, F.H., Atlas of Human Anatomy, 2nd E. (1997) (“Netter”)
Ex. 1025	U.S. Pat. No. 5,902,598 to Chen <i>et al.</i> (filed Aug. 28, 1997) (“Chen”)
Ex. 1026	US Application Publication No. 2005/0095269 to Ainpour <i>et al.</i> (filed Nov. 4, 2003) (“Ainpour”)
Ex. 1027	US Patent No. 4,327,725 to Cortese <i>et al.</i> (filed Nov. 25, 1980) (“Cortese”)
Ex. 1028	US Patent No. 5,124,392 to Robertson <i>et al.</i> (filed May 31, 1990) (“Robertson”)
Ex. 1029	Baxter <i>et al.</i> , Punctal Plugs in the Management of Dry Eyes, 2 THE OCULAR SURFACE, 255-265 (October 2004) (“Baxter”)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.